Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)DiseasePolycythaemia VeraSubgroupICD10D45MeSHPolycythemia VeraSequenceChemotherapyChemo-substanceBusulfanHydroxyureaRopeginterferon alfa-2bRuxolitinibChemo-substanceBusulfanHydroxyureaRopeginterferon alfa-2bRuxolitinibChemo-substanceBusulfanHydroxyureaRopeginterferon alfa-2bRuxolitinibChemo-substanceBusulfanHydroxyureaRopeginterferon alfa-2bRuxolitinibNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationSecond lineseveral possibleTherapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlArthalgiaAstheniaConstipationDepressionDiarrheaDrowsinessDyspneaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFlu-like SymptomsHeadacheHypothyroidismInfectionsLeukopeniaNeutropeniaPainPruritusPyrexiaThrombocytopenia below 50 000/µl only studiesPublicationAuthorGisslinger HKuriakose ETMesa RVannucchi ADiseasePolycythaemia vera, HU, IFNa resistent oder intolerant, Patienten in fortgeschrittenem LebensalterPolycythaemia vera, Phlebotomie-abhängig, ECOG 0-2Polycythaemia vera, Phlebotomie-abhängig oder symptomatischPolycythemia vera, Erstline, ECOG 0-2OriginAzienda Ospedaliera–Universitaria Careggi, University of Florence, RESPONSE trialMayo Clinic Cancer Center, Scottsdale, AZ, USA, RELIEFMedical University of ViennaWeill Cornell Medical College, New York, USAProtocols in Revision 4 protocols foundProtocols under revision.Busulfan 2, Polycythaemia Vera (PID2299 V1.0)Hydroxyurea 15, Polycythaemia Vera (PID9 V1.0)Ropeginterferon Alfa-2b, Polycythaemia Vera (PID1249 V1.0)Ruxolitinib 10, Polycythaemia Vera (PID899 V1.1)
